Atlas Trials

Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older

Clinical trial NCT04974216 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04974216
Sponsor
The Lymphoma Academic Research Organisation
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
DLBCL
Start date
2021-12-20
Primary completion
2024-07-15
Enrollment
71

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.